An Open-label Phase Ib Study Of Palbociclib (Oral Cdk 4/6 Inhibitor) Plus Abraxane (Registered) (Nab-paclitaxel) In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Palbociclib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Sep 2017 Planned End Date changed from 1 Sep 2018 to 18 Sep 2018.
- 11 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 18 Sep 2018.
- 10 Jun 2017 Biomarkers information updated